Related Experiment Video
Updated: Jul 30, 2025
10:25
Author Spotlight: Integrating High-Resolution Intravital Imaging and MRI to Enhance Stereotactic Body Radiation Therapy Planning
Published on: April 12, 2024
1.5K
Intraoperative molecular imaging: 3rd biennial clinical trials update.
Patrick Bou-Samra1, Najib Muhammad1, Austin Chang1
1University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, United States.
Journal of Biomedical Optics
|May 16, 2023
Summary
Intraoperative molecular imaging (IMI) enhances precision cancer surgery using optical contrast agents. Ongoing trials and new techniques show IMI
Area of Science:
- Oncology
- Surgical Innovation
- Medical Imaging
Background:
- Intraoperative molecular imaging (IMI) is advancing precision cancer surgery.
- Optical contrast agents are key to developing new surgical endpoints.
Purpose of the Study:
- To review the latest clinical trials and preclinical advancements in IMI for cancer surgery.
- To discuss the application of various optical contrast agents and imaging techniques.
Main Methods:
- Presentation of ongoing clinical trials and endpoints by principal investigators.
- Discussion of FDA-approved and investigational dyes (phase 1-3 trials).
- Exploration of bench-to-bedside translation, pediatric dyes, and nonfluorescence-based imaging.
Main Results:
- IMI has demonstrated clinical significance in improving cancer surgery outcomes.
- Diverse applications of IMI across multiple surgical subspecialties were highlighted.
- New dyes and imaging techniques are under development.
Conclusions:
- Intraoperative molecular imaging is a valuable tool for precision cancer surgery and clinical decision-making.
- Further development of dyes and imaging techniques is needed.
- Expanding IMI utilization in specific subspecialties remains a goal.
